Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 432

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma

Open access
Maranchie, Jodi K, Vasselli, James R, Riss, Joseph, Bonifacino, Juan S, Linehan, W.Marston, Klausner, Richard D·2002·Cancer Cell
DOI 10.1016/s1535-6108(02)00044-2
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1535-6108(02)00044-2

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 35

  1. Ananth, 1999, Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma, Cancer Res., 59, 2210
  2. Bhattacharya, 1999, Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1, Genes Dev., 13, 64, 10.1101/gad.13.1.64 · DOI · Paper page
  3. Bunn, 1998, Erythropoietin, J. Exp. Biol., 201, 1197, 10.1242/jeb.201.8.1197 · DOI · Paper page
  4. Choyke, 1995, von Hippel-Lindau disease, Radiology, 194, 629, 10.1148/radiology.194.3.7862955 · DOI · Paper page
  5. Cockman, 2000, Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein, J. Biol. Chem., 275, 25733, 10.1074/jbc.M002740200 · DOI · Paper page
  6. Duan, 1995, Inhibition of transcription elongation by the VHL tumor suppressor protein, Science, 269, 1402, 10.1126/science.7660122 · DOI · Paper page
  7. Epstein, 2001, C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation, Cell, 107, 43, 10.1016/S0092-8674(01)00507-4 · DOI · Paper page
  8. Favier, 1999, Cloning and expression pattern of EPAS1 in the chicken embryo. Colocalization with tyrosine hydroxylase, FEBS Lett., 462, 19, 10.1016/S0014-5793(99)01476-3 · DOI
  9. Flamme, 1997, HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 α and developmentally expressed in blood vessels, Mech. Dev., 63, 51, 10.1016/S0925-4773(97)00674-6 · DOI · Paper page
  10. Flamme, 1998, Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2α, Am. J. Pathol., 153, 25, 10.1016/S0002-9440(10)65541-1 · DOI
  11. Foster, 1994, Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma, Hum. Mol. Genet., 3, 2169, 10.1093/hmg/3.12.2169 · DOI · Paper page
  12. Giatromanolaki, 2001, Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival, Br. J. Cancer, 85, 881, 10.1054/bjoc.2001.2018 · DOI · Paper page
  13. Herman, 1994, Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma, Proc. Natl. Acad. Sci. USA, 91, 9700, 10.1073/pnas.91.21.9700 · DOI · Paper page
  14. Iliopoulos, 1995, Tumour suppression by the human von Hippel-Lindau gene product, Nat. Med., 1, 822, 10.1038/nm0895-822 · DOI · Paper page
  15. Iliopoulos, 1996, Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein, Proc. Natl. Acad. Sci. USA, 93, 10595, 10.1073/pnas.93.20.10595 · DOI · Paper page
  16. Jain, 1998, Expression of ARNT, ARNT2, HIF1 α, HIF2 α and Ah receptor mRNAs in the developing mouse, Mech. Dev., 73, 117, 10.1016/S0925-4773(98)00038-0 · DOI · Paper page
  17. Kamura, 1999, Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase, Science, 284, 657, 10.1126/science.284.5414.657 · DOI · Paper page
  18. Kibel, 1995, Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C, Science, 269, 1444, 10.1126/science.7660130 · DOI · Paper page
  19. Koochekpour, 1999, The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells, Mol. Cell. Biol., 19, 5902, 10.1128/MCB.19.9.5902 · DOI · Paper page
  20. Kotani, 1994, Improved methods of retroviral vector transduction and production for gene therapy, Hum. Gene Ther., 5, 19, 10.1089/hum.1994.5.1-19 · DOI · Paper page
  21. Kotch, 1999, Defective vascularization of HIF-1α-null embryos is not associated with VEGF deficiency but with mesenchymal cell death, Dev. Biol., 209, 254, 10.1006/dbio.1999.9253 · DOI · Paper page
  22. Ohh, 1998, The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix, Mol. Cell, 1, 959, 10.1016/S1097-2765(00)80096-9 · DOI · Paper page
  23. Pause, 1997, The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins, Proc. Natl. Acad. Sci. USA, 94, 2156, 10.1073/pnas.94.6.2156 · DOI · Paper page
  24. Pause, 1998, The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal, Proc. Natl. Acad. Sci. USA, 95, 993, 10.1073/pnas.95.3.993 · DOI · Paper page
  25. Pause, 1999, Studying interactions of four proteins in the yeast two-hybrid system, Proc. Natl. Acad. Sci. USA, 96, 9533, 10.1073/pnas.96.17.9533 · DOI
  26. Salceda, 1997, Complex role of protein phosphorylation in gene activation by hypoxia, Kidney Int., 51, 556, 10.1038/ki.1997.78 · DOI
  27. Semenza, 1992, A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation, Mol. Cell. Biol., 12, 5447, 10.1128/MCB.12.12.5447 · DOI · Paper page
  28. Semenza, 1999, Regulation of cardiovascular development and physiology by hypoxia-inducible factor 1, Ann. N Y Acad. Sci., 874, 262, 10.1111/j.1749-6632.1999.tb09241.x · DOI
  29. Siemeister, 1996, Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein, Cancer Res., 56, 2299
  30. Tacchini, 2001, Hepatocyte growth factor signalling stimulates hypoxia inducible factor- 1 (HIF-1) activity in HepG2 hepatoma cells, Carcinogenesis, 22, 1363, 10.1093/carcin/22.9.1363 · DOI · Paper page
  31. Tian, 1997, Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells, Genes Dev., 11, 72, 10.1101/gad.11.1.72 · DOI · Paper page
  32. Tian, 1998, The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development, Genes Dev., 12, 3320, 10.1101/gad.12.21.3320 · DOI · Paper page
  33. Wiesener, 1998, Induction of endothelial PAS domain protein-1 by hypoxia, Blood, 92, 2260, 10.1182/blood.V92.7.2260 · DOI · Paper page
  34. Wykoff, 2001, The HIF pathway, Novartis Found. Symp., 240, 212, 10.1002/0470868716.ch15 · DOI
  35. Zhong, 1999, Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases, Cancer Res., 59, 5830

Cited by

See all 432

Metadata

Authors
Maranchie, J. K., Vasselli, J. R., Riss, J., Bonifacino, J. S., Linehan, W. M., & Klausner, R. D.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2002-04
Volume
1
Issue
3
Pages
247-255
ISSN
1535-6108 (ISSN-L)
DOI
10.1016/s1535-6108(02)00044-2
OpenAlex
W2042702043
Cited by
432
References
8
FWCI
10.99
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. https://app.cochat.ai/papers/10.1016/s1535-6108(02)00044-2
The paper
Maranchie, J. K., Vasselli, J. R., Riss, J., Bonifacino, J. S., Linehan, W. M., & Klausner, R. D. (2002). The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell. https://doi.org/10.1016/s1535-6108(02)00044-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.